Division of Infectious Diseases, Geneva University Hospitals, 1211 Geneva, Switzerland.
Laboratory of Virology, Division of Laboratory Medicine, Geneva University Hospitals, 1211 Geneva, Switzerland.
Viruses. 2023 Apr 7;15(4):928. doi: 10.3390/v15040928.
Metagenomics revealed novel and routinely overlooked viruses, representing sources of unrecognized infections after allogeneic hematopoietic stem cell transplantation (allo-HSCT). We aim to describe DNA and RNA virus prevalence and kinetics in allo-HSCT recipients' plasma for one year post HSCT. We included 109 adult patients with first allo-HSCT from 1 March 2017 to 31 January 2019 in this observational cohort study. Seventeen DNA and three RNA viral species were screened with qualitative and/or quantitative r(RT)-PCR assays using plasma samples collected at 0, 1, 3, 6, and 12 months post HSCT. TTV infected 97% of patients, followed by HPgV-1 (prevalence: 26-36%). TTV (median 3.29 × 10 copies/mL) and HPgV-1 (median 1.18 × 10 copies/mL) viral loads peaked at month 3. At least one virus (BKPyV, JCPyV, MCPyV, HPyV6/7) was detected in >10% of patients. HPyV6 and HPyV7 prevalence reached 27% and 12% at month 3; CMV prevalence reached 27%. HSV, VZV, EBV, HHV-7, HAdV and B19V prevalence remained <5%. HPyV9, TSPyV, HBoV, EV and HPg-V2 were never detected. At month 3, 72% of patients had co-infections. TTV and HPgV-1 infections were highly prevalent. BKPyV, MCPyV and HPyV6/7 were frequently detected relative to classical culprits. Further investigation is needed into associations between these viral infections and immune reconstitution or clinical outcomes.
宏基因组学揭示了新型且经常被忽视的病毒,这些病毒是异基因造血干细胞移植(allo-HSCT)后未被识别的感染源。我们旨在描述 allo-HSCT 受者血浆中 DNA 和 RNA 病毒的流行率和动力学,为期一年。我们纳入了这项观察性队列研究中的 109 例于 2017 年 3 月 1 日至 2019 年 1 月 31 日接受首次 allo-HSCT 的成年患者。使用定性和/或定量 r(RT)-PCR 检测方法,在 HSCT 后 0、1、3、6 和 12 个月采集血浆样本,筛选出 17 种 DNA 和 3 种 RNA 病毒。TTV 感染了 97%的患者,其次是 HPgV-1(流行率:26-36%)。TTV(中位数 3.29×10 拷贝/mL)和 HPgV-1(中位数 1.18×10 拷贝/mL)病毒载量在第 3 个月达到峰值。至少有一种病毒(BKPyV、JCPyV、MCPyV、HPyV6/7)在>10%的患者中被检测到。HPyV6 和 HPyV7 的流行率在第 3 个月达到 27%和 12%;CMV 的流行率达到 27%。HSV、VZV、EBV、HHV-7、HAdV 和 B19V 的流行率仍<5%。HPyV9、TSPyV、HBoV、EV 和 HPg-V2 从未被检测到。在第 3 个月,72%的患者发生合并感染。TTV 和 HPgV-1 感染非常普遍。与经典病原体相比,BKPyV、MCPyV 和 HPyV6/7 经常被检测到。需要进一步研究这些病毒感染与免疫重建或临床结局之间的关系。